Select your country

STADA: STADA allows elaborated motion from Active Ownership Fund as supplement to the Annual General Meeting 2016

  • 13/05/2016

Bad Vilbel, May 13, 2016 – STADA Arzneimittel AG has received an elaborated motion from Active Ownership Fund SICAV-FIS SCS as a supplement to the agenda of the STADA Annual General Meeting 2016. STADA conducted a review of the motion and published it on its website.
On May 6, 2016, Active Ownership Fund had submitted an agenda amendment motion to the Company, which the investor has now elaborated on. Accordingly, the investor now proposes three instead of five new candidates for election as shareholder representatives on the Supervisory Board.
Within the scope of its discretionary powers, the STADA Executive Board decided to allow the agenda amendment motion in order to avoid the substantial costs that would have been incurred in the case of legal action from Active Ownership Fund to assert their request or the convening of an extraordinary Annual General Meeting.
The Executive Board sees its obligations first and foremost in the well-being of the company. For this reason, it would like to ensure a quick decision in this matter. The Executive Board can thus concentrate on the further implementation of the successful growth strategy in order to create value for the company’s shareholders.
It is now up to the shareholders to vote on the motion from Active Ownership Fund at the Annual General Meeting on June 9, 2016.
STADA Chairman of the Supervisory Board Dr. Martin Abend commented on the elaborated motion as follows: “In the interest of good corporate governance, it is important to us that Supervisory Board members are elected at the Annual General Meeting. Because we on the Supervisory Board had already begun to look at questions related to the succession planning process some time ago, a constructive dialog about the qualified candidates, which I welcome, has taken place with Active Ownership Fund”.
 
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Tel.: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de


Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: press@stada.de